138 related articles for article (PubMed ID: 32329688)
1. The Therapeutic Potential of MEK1/2 Inhibitors in the Treatment of Gynecological Cancers: Rational Strategies and Recent Progress.
Ghanaatgar-Kasbi S; Khazaei M; Rastgar-Moghadam A; Ferns GA; Hassanian SM; Avan A
Curr Cancer Drug Targets; 2020; 20(6):417-428. PubMed ID: 32329688
[TBL] [Abstract][Full Text] [Related]
2. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
Miller CR; Oliver KE; Farley JH
Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.
Daouti S; Wang H; Li WH; Higgins B; Kolinsky K; Packman K; Specian A; Kong N; Huby N; Wen Y; Xiang Q; Podlaski FJ; He Y; Fotouhi N; Heimbrook D; Niu H
Cancer Res; 2009 Mar; 69(5):1924-32. PubMed ID: 19244124
[TBL] [Abstract][Full Text] [Related]
4. The biology and clinical development of MEK inhibitors for cancer.
Luke JJ; Ott PA; Shapiro GI
Drugs; 2014 Dec; 74(18):2111-28. PubMed ID: 25414119
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
[TBL] [Abstract][Full Text] [Related]
6. Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas.
Roskoski R
Pharmacol Res; 2017 Mar; 117():20-31. PubMed ID: 27956260
[TBL] [Abstract][Full Text] [Related]
7. The clinical development of MEK inhibitors.
Zhao Y; Adjei AA
Nat Rev Clin Oncol; 2014 Jul; 11(7):385-400. PubMed ID: 24840079
[TBL] [Abstract][Full Text] [Related]
8. MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.
Wu PK; Park JI
Semin Oncol; 2015 Dec; 42(6):849-62. PubMed ID: 26615130
[TBL] [Abstract][Full Text] [Related]
9. Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer.
Wang C; Wang H; Zheng C; Liu Z; Gao X; Xu F; Niu Y; Zhang L; Xu P
Eur J Med Chem; 2021 Jun; 218():113386. PubMed ID: 33774345
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
11. MEK and the inhibitors: from bench to bedside.
Akinleye A; Furqan M; Mukhi N; Ravella P; Liu D
J Hematol Oncol; 2013 Apr; 6():27. PubMed ID: 23587417
[TBL] [Abstract][Full Text] [Related]
12. MEK inhibitors under development for treatment of non-small-cell lung cancer.
Kim C; Giaccone G
Expert Opin Investig Drugs; 2018 Jan; 27(1):17-30. PubMed ID: 29216787
[TBL] [Abstract][Full Text] [Related]
13. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
Iverson C; Larson G; Lai C; Yeh LT; Dadson C; Weingarten P; Appleby T; Vo T; Maderna A; Vernier JM; Hamatake R; Miner JN; Quart B
Cancer Res; 2009 Sep; 69(17):6839-47. PubMed ID: 19706763
[TBL] [Abstract][Full Text] [Related]
14. CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo.
Kim DJ; Lee MH; Reddy K; Li Y; Lim DY; Xie H; Lee SY; Yeom YI; Bode AM; Dong Z
Carcinogenesis; 2013 May; 34(5):1134-43. PubMed ID: 23354306
[TBL] [Abstract][Full Text] [Related]
15. Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation.
Wang H; Daouti S; Li WH; Wen Y; Rizzo C; Higgins B; Packman K; Rosen N; Boylan JF; Heimbrook D; Niu H
Cancer Res; 2011 Aug; 71(16):5535-45. PubMed ID: 21705440
[TBL] [Abstract][Full Text] [Related]
16. Novel mitogen-activated protein kinase kinase inhibitors.
Chapman MS; Miner JN
Expert Opin Investig Drugs; 2011 Feb; 20(2):209-20. PubMed ID: 21235429
[TBL] [Abstract][Full Text] [Related]
17. Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.
Mandal R; Becker S; Strebhardt K
Oncogene; 2016 May; 35(20):2547-61. PubMed ID: 26364606
[TBL] [Abstract][Full Text] [Related]
18. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
Inaba K; Oda K; Ikeda Y; Sone K; Miyasaka A; Kashiyama T; Fukuda T; Uehara Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Yano T; Osuga Y; Fujii T
Gynecol Oncol; 2015 Aug; 138(2):323-31. PubMed ID: 26033306
[TBL] [Abstract][Full Text] [Related]
20. In silico investigation of new binding pocket for mitogen activated kinase kinase (MEK): Development of new promising inhibitors.
Yari H; Ganjalikhany MR; Sadegh H
Comput Biol Chem; 2015 Dec; 59 Pt A():185-98. PubMed ID: 26580563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
